What is your general approach to PARPi usage in the front-line and recurrent ovarian cancer setting in light of FDA label changes over the years?

In the frontline setting, I generally recommend PARP inhibition with olaparib x2 years for BRCAmut patients (1) and with niraparib x2-3 years for patients with HR-deficient tumors (I personally tend to do 2 years, based on SOLO1 data with olaparib) (2). For BRCAwt patients with HR-proficient tumors...